<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04215120</url>
  </required_header>
  <id_info>
    <org_study_id>DESI.19.001.01</org_study_id>
    <nct_id>NCT04215120</nct_id>
  </id_info>
  <brief_title>Desidustat in the Treatment of Anemia in CKD on Dialysis Patients</brief_title>
  <acronym>DREAM-D</acronym>
  <official_title>A Phase 3, Multicenter, Open-label, Randomized, Active-controlled Study to Evaluate the Efficacy and Safety of Desidustat Tablet Versus Epoetin Alfa Injection for the Treatment of Anemia in Patients With Chronic Kidney Disease (CKD) on Dialysis (DREAM-D)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cadila Healthcare Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cadila Healthcare Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 3, multicenter, open-label, randomized, active-controlled study to evaluate the
      efficacy and safety of Desidustat Tablet versus Epoetin alfa Injection for the treatment of
      anemia in patients with CKD on dialysis. (DREAM-D)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin level</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in Hb levels from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin Response</measure>
    <time_frame>24 weeks</time_frame>
    <description>No. of subjects with Hb response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin target range</measure>
    <time_frame>24 weeks</time_frame>
    <description>Time to achieve target range Hb level</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">392</enrollment>
  <condition>Chronic Kidney Disease Stage 5 on Dialysis</condition>
  <arm_group>
    <arm_group_label>Desidustat oral tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomly assigned to receive Desidustat 100 mg in a 1:1 ratio for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epoetin Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomly assigned to receive Epoetin in a 1:1 ratio for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desidustat Oral Tablet</intervention_name>
    <description>Desidustat tablet</description>
    <arm_group_label>Desidustat oral tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin Alfa</intervention_name>
    <description>Epoetin Injection</description>
    <arm_group_label>Epoetin Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Ability to understand and give informed consent for participation. 2. Hemoglobin values
        during the screening period must be 8-11 g/dL (both inclusive).

        3.

          1. Patients will be considered not treated with erythropoietin analogue (Epoetin and
             Darbepoeitin) if they have not received erythropoietin analogue for at least 4 weeks
             and Mircera® for at least 8 weeks prior to screening visit. OR

          2. Patients who are on ESA therapy must be on stable dose for 4 weeks prior to enrollment
             (≤30% of dose change).

             4. Patients on hemodialysis (≥2 times in a week) for at least 12 weeks prior to
             screening visit and have access consisting of an arteriovenous fistula, AV graft, or
             catheter (permanent/temporary).

             5. Patients with no planned change in dialysis modality and with no planned renal
             transplant during study period.

             6. Left ventricular ejection fraction ≥40% by echocardiogram prior to randomization.

             7. No iron, folate or Vitamin B12 deficiency.

             8. Females of childbearing potential, must agree to use one of the approved
             contraception methods, from screening until completion of the follow-up visit.

             Exclusion Criteria:

               1. Red blood cell transfusion within 8 weeks prior to participating in the study.

               2. History of previous or concurrent cancer.

               3. Serologic status reflecting active hepatitis B or C infection or Human
                  immunodeficiency virus (HIV) infection.

               4. Active infection at initiation of study.

               5. History of renal transplant.

               6. Uncontrolled hypertension (defined as SBP &gt;180 mmHg or DBP &gt;100 mmHg) at
                  screening visit (before dialysis).

               7. Patient on high rhEPO dose at screening visit. [High dose defined as an epoetin
                  dose of ≥450 IU/kg/week intravenous or ≥ 300 IU/kg/week subcutaneous or
                  darbepoetin dose of ≥1.5 µg/kg/week subcutaneous].

               8. Major surgery within 90 days of the first day of study drug dosing, and minor
                  surgery within 30 days of the first day of study drug dosing.

               9. Unable to swallow tablets or disease significantly affecting gastrointestinal
                  function and/or inhibiting small intestine absorption such as; malabsorption
                  syndrome, resection of the small bowel or poorly controlled inflammatory bowel
                  disease affecting the small intestine.

              10. History of uncontrolled autoimmune hemolytic anemia, idiopathic thrombocytopenic
                  purpura (ITP) or thalassemia.

              11. Presence or a history of bleeding disorders or clinical conditions (e.g.
                  gastrointestinal [GI] bleeding or constitutional disorders) that may increase
                  risk of life-threatening bleeding.

              12. History of stroke or intracranial hemorrhage within 6 months prior to enrollment.

              13. History of allergic reactions attributed to compounds of similar chemical or
                  biologic composition to Desidustat or Epoetin alfa or to any
                  erythropoieisis-stimulating agent.

              14. Pregnant and breastfeeding women.

              15. Current life-threatening illness, medical condition or organ system dysfunction
                  which, in the Investigator's opinion, could compromise the patient's safety.

              16. Other laboratory abnormalities that, in the opinion of the investigator, would
                  compromise the patient's safety or interfere with data interpretation.

              17. Presence of other clinically significant systemic disorders or diseases (e.g.,
                  respiratory, gastrointestinal, endocrine, immunological, dermatological,
                  neurological, psychiatric disease or any other body system involvement) which, in
                  the Investigator's opinion, could compromise the patient's safety.

              18. History of significant alcoholism or drug abuse within the past 1 year. History
                  or presence of significant smoking (more than 10 cigarettes per day) or
                  consumption of tobacco/nicotine products (more than 10 times per day).

              19. History of difficulty with donating blood.

              20. History or presence of any clinically significant electrocardiogram (ECG)
                  abnormalities during screening.

              21. Participants who have participated in any drug research study other than the
                  present trial within past 3 months.

              22. Participants who have donated one unit (350 ml) of blood in the past 3 months or
                  history of whole blood transfusion in last 120 days prior to entry in the study.

              23. Existing clinically active chronic inflammatory disease (RA, Celiac disease, UC,
                  Crohns disease)

              24. In case of DM patients, HbA1c &gt;9%.

              25. Female volunteers with following criteria will not be recruited:

                    -  History of pregnancy or lactation in the past 3 months

                    -  Fertile female volunteers not protected against pregnancy by adequate long-
                       term anti-fertility measures

                    -  History of less than 1 year of menopause and not using adequate long-term
                       anti-fertility measures

                    -  Positive urine pregnancy test at Visit 2

                    -  Positive serum β-hCG level at the screening visit

              26. Currently active clinically significant cardiovascular disease such as
                  uncontrolled arrhythmia, congestive heart failure, any class 3 or 4 cardiac
                  disease as defined by the New York Heart Association Functional Classification or
                  history of myocardial infarction prior to first dose with study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Deven Parmar, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cadila Healthcare Limited</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr Deven Parmar, MD</last_name>
    <phone>+912717665555</phone>
    <phone_ext>451</phone_ext>
    <email>deven.parmar@zyduscadila.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dr Kevin kansagra, MD</last_name>
    <phone>+912717665555</phone>
    <phone_ext>279</phone_ext>
    <email>kevinkumar.kansagra@zyduscadila.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Karnavati Hospital Pvt.Ltd</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380006</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Javed M Vakil</last_name>
      <phone>9824919119</phone>
      <email>jmvakil@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shalby Hospital,</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380015</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Kamal Goplani</last_name>
      <phone>9512016866</phone>
      <email>kamalgoplani@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DHS Multispecialty Hospital</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380054</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Siddharth Mavani</last_name>
      <phone>9825317953</phone>
      <email>msiddh@yahoo.co.in</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chopda Medicare &amp; Research Centre Pvt. Ltd</name>
      <address>
        <city>Nashik</city>
        <state>Maharashtra</state>
        <zip>422005</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Kailas Shewale</last_name>
      <phone>9960500350</phone>
      <email>kailashshewale@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aditya Birla Memorial Hospital</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411033</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Tarun Jaloka</last_name>
      <phone>9370691221</phone>
      <email>tjeloka@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eternal Hospital</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302017</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Ashok Kumar Sharma</last_name>
      <phone>9829065210</phone>
      <email>draksharma_50@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Star Hospital</name>
      <address>
        <city>Hyderabad</city>
        <state>Telangana</state>
        <zip>500034</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Rajasekara M</last_name>
      <phone>9391059322</phone>
      <email>rajasekarac@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 22, 2019</study_first_submitted>
  <study_first_submitted_qc>December 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>December 28, 2019</last_update_submitted>
  <last_update_submitted_qc>December 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

